Tag - Chronix Biomedical

Oncocyte Agrees to Enter Licensing and Collaboration Agreement with Chronix Biomedical

Ziad2022-11-25T14:02:27-05:00 Oncocyte Corporation, a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that it has agreed to enter a licensing and collaboration agreement with Chronix Biomedical. Oncocyte is licensing Chronix’s patented CNI Monitor technology for the TheraSure™-CNI MONITOR clinical assay. Read more >>

Chronix Biomedical $8.00 million Fundraising. John DiPietro Filed Jul 18 SEC Filing

Ziad2022-11-25T14:05:41-05:00Chronix Biomedical Inc, Corporation just had published form D about $8.00 million equity financing. This is a new filing. Chronix Biomedical was able to sell $3.31 million so far. That is 41.34 % of the fundraising. The total financing amount was $8.00 million. This form was filed on 2017-07-18. The reason for the financing was: unspecified. The fundraising still has about $4.69 million more and is not closed yet. We have to wait more to see if the offering will...

Chronix presents head/neck cancer data at ASCO

Ziad2022-11-25T14:05:42-05:00Chronix Biomedical presents positive data on prognostic test in head/neck cancer study at ASCO. Read more >>

Chronix’s ASCO presentation abstract disclosure

Ziad2022-11-25T14:05:42-05:00Chronix Biomedical, Inc., a developer of novel blood-based cancer molecular diagnostics, notes the formal disclosure of the abstract covering its forthcoming presentation of its study in head and neck cancer at the American Society of Clinical Oncology ('ASCO') Annual Meeting on 5 June. Read more >>

Chronix Biomedical Study Demonstrates Its Blood Test Can Predict Response To Cancer Immunotherapy

Ziad2022-11-25T14:05:53-05:00Chronix Biomedical, Inc., a developer of novel cancer blood-based molecular diagnostics, announces the publication of positive results of a study using its circulating cell-free tumour DNA-based test as a means to predict therapeutic response to immunotherapy in multiple solid tumour types. Read more >>

Chronix provides update on studies & presentations

Ziad2022-11-25T14:05:54-05:00Chronix Biomedical, Inc., a developer of blood-based molecular diagnostics, is pleased to report the successful outcome of two pilot studies of its liquid biopsy test for assessing the response to treatment in different solid tumour types. Chronix’s tests use proprietary algorithms to derive a copy number instability (CNI) score from sequencing of circulating cell-free tumour DNA (cfDNA), which can be used in the prognosis, diagnosis and monitoring of therapeutic response to cancer. Read more >>

BRIEF-Chronix Biomedical Inc raises about $5 mln in equity financing

Ziad2022-11-25T14:06:06-05:00Chronix Biomedical Inc says it has raised about $5 million in equity financing from total offering amount of amount $5 million. Read more >>